Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157319 | 0.90 | DRD3 (0.48) | HRH3EPHX2KCNA5DRD3HRH2 | |
| SCHEMBL2157220 | 0.90 | HRH3 (0.53) | HRH3EPHX2PANK3KCNA5DRD3 | |
| SCHEMBL2157289 | 0.89 | DRD3 (0.47) | EPHX2KCNA5DRD3KCNH2HRH2 | |
| SCHEMBL2157561 | 0.88 | KCNA5 (0.57) | HRH3EPHX2PANK3KCNA5DRD3 | |
| SCHEMBL2157592 | 0.87 | POLB (0.45) | KCNH2L3MBTL1POLB | |
| SCHEMBL2158392 | 0.82 | SIGMAR1 (0.43) | EPHX2KCNA5DRD3HRH2HRH1 | |
| SCHEMBL2157523 | 0.80 | KCNA5 (0.49) | EPHX2KCNA5DRD3HRH2HRH1 | |
| Hydrochloric Acid SCHEMBL2158399 | 0.80 | KCNA5 (0.48) | HRH3EPHX2KCNA5DRD3KCNH2 | |
| SCHEMBL2157515 | 0.79 | EPHX2 (0.44) | EPHX2DRD3KCNH2HRH2HRH1 | |
| SCHEMBL2157502 | 0.79 | DRD3 (0.51) | EPHX2KCNA5DRD3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-2340835-A1 | Piperidine and piperazine derivatives | M's Science Corporation (JP) | 2011-07-06 | — | — | EP | disclosed |
| EP-1976525-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SUN CONNIE L | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SIGMAR1, OPRM1, OPRD1 | HRH3 158/4885EPHX2 2613/4885PANK3 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.